Philip Martin
YOU?
Author Swipe
View article: California farmers are turning to nonfarm employers to fill lower wage seasonal jobs
California farmers are turning to nonfarm employers to fill lower wage seasonal jobs Open
California’s agricultural employers hired an average 414,000 workers between 2018 and 2023 and reported an average 886,000 unique farmworkers each year, a ratio of 2.1 workers for each average or full-time equivalent (FTE) job. The ratio o…
View article: Farm Guest Workers: US Experience
Farm Guest Workers: US Experience Open
The US was one of the first countries to develop farm guest worker programs with Bracero programs during WWI and WWII outside regular immigration laws, followed by the H‐2(A) farm guest worker programme included in immigration law in the 1…
View article: California has 882,000 farmworkers to fill 413,000 jobs
California has 882,000 farmworkers to fill 413,000 jobs Open
California's agricultural employers hired an average of 413,000 workers between 2018 and 2021 and reported an average of 882,000 farmworkers during these years, a ratio of 2.1 workers for each job. Average agricultural employment has been …
View article: Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot Study
Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot Study Open
Introduction: Generating high levels of immunosuppressive adenosine (ADO) in the tumor microenvironment contributes to cancer immune evasion. CD39 and CD73 hydrolyze adenosine triphosphate into ADO; thus, efforts have been ma…
View article: NIMG-21. SERIAL QUANTITATIVE MRI RADIOMICS SIGNATURE FOR PREDICTION OF SURVIVAL IN GLIOBLASTOMA – A PILOT STUDY
NIMG-21. SERIAL QUANTITATIVE MRI RADIOMICS SIGNATURE FOR PREDICTION OF SURVIVAL IN GLIOBLASTOMA – A PILOT STUDY Open
INTRODUCTION Radiomics in glioblastoma (GBM) imaging incorporates mathematical and statistical quantification of complex imaging features as surrogate biomarkers of tumour physiology. Delta-radiomics extends this capability by monitoring c…
View article: Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue Open
Background Quantification of drug-target binding is critical for confirming that drugs reach their intended protein targets, understanding the mechanism of action, and interpreting dose-response relationships. For covalent inhibitors, targ…
View article: More jobs and less seasonal employment in California agriculture since 1990
More jobs and less seasonal employment in California agriculture since 1990 Open
Employment in California agriculture has increased over the past 30 years and has become less seasonal. There were an average of 404,000 farm jobs in California in 2020, 10% more than average employment of 367,000 in 1990. Meanwhile, seaso…
View article: First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors Open
Background CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced co…
View article: Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Antitumor efficacy of TNFRSF agonist immunotherapies in CT26 STK11wt or KO mice. Survival of mice engrafted with (A) CT26 WT or (B) CT26 STK11 KO clone 26C16 treated with isotype control antibodies, anti-PD-L1 plus anti-CTLA-4 mAbs or immu…
View article: Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Characterization of innate and adaptive immune cell recruitment to CT26 STK11 KO tumors compared to CT26 WT. (A) Work flow for single cell RNA (scRNA) analysis of CD45+ cells isolated from CT26 WT and STK11 KO clones. Data analysis includi…
View article: Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
List of genes differentially expressed in STK11mut vs STK11wt tumors.
View article: Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Suppressive activity of MDSCs isolated from CT26 WT or CT26 SKT11 KO tumors and pharmacological reversal by STAT3 ASO treatment in the CT26 WT model. (A) Percentage of naive T cell proliferation by anti-CD3/CD28/IL2 stimulation in the pres…
View article: Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the monocyte-macrophage-DC subpopulations identified in Supplementary Figure 5H. Only genes with adjusted p-value < 0.01 and average log fold-change > 0.3 were included. gene, gene name; p_val, p-value calculated based on …
View article: Supplementary Table S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Kaplan-Meier analysis using a log rank (Mantel-Cox) test to compare survival among the treatment groups represented in Figure 5. A total of 9 comparisons between groups were conducted. P-values were not adjusted for multiple comparisons.
View article: Supplementary Figure S11 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S11 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Efficacy of anti-IL6 mAb in CT26 STK11 KO model. (A) Survival of mice engrafted with 26C16 and treated as indicated. Isotype vs anti-PD-L1 plus anti-CTLA-4, p = 0.0020; Isotype vs anti-IL6 plus anti-PD-L1 plus anti-CTLA-4, p = 0.034; anti-…
View article: Supplementary Figure S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Characterization of STAT3 phosphorylation in the CT26 STK11 KO model and from primary human NSCLC tumors. (A) Representative multispectral fluorescence imaging of phosphorylated murine STAT3 (pSTAT3), CD45, CD163, and nuclei (DAPI), as ind…
View article: Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Time to 50% survival, in days, for mice engrafted with EMT6 tumors left untreated or treated with isotype control Ab or anti-PD-L1 plus anti-CTLA-4.
View article: Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
CPI efficacy in EMT6 STK11wt, KO, and KO/KI tumors. (A) Western blotting of STK11, phosphorylated AMPK (p-AMPK), total AMPK, and actin in lysates from wild-type EMT6 cells (EMT6 WT), STK11 CRISPR KO clone (EMT6 KO) and from STK11 KO clone …
View article: Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Dependence of STAT3 ASO and combination treatment efficacy on CD8+ or CD4+ T cells in CT26 STK11 KO clone 26C16. Efficacy of STAT3 ASO, CPIs, and combination treatments as indicated in mice pre-treated with (A) control antibody, (B) anti-C…
View article: Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the lymphocyte subpopulations identified in Supplementary Figure 6. Only genes with adjusted p-value < 0.01 and average log fold-change > 0.3 were included. gene, gene name; p_val, p-value calculated based on Wilcoxon test…
View article: Supplementary Table S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Cytokines and other soluble factors evaluated in the baseline serum of patients with STK11mut or STK11wt tumors.
View article: Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Antitumor efficacy of TNFRSF agonist immunotherapies in CT26 STK11wt or KO mice. Survival of mice engrafted with (A) CT26 WT or (B) CT26 STK11 KO clone 26C16 treated with isotype control antibodies, anti-PD-L1 plus anti-CTLA-4 mAbs or immu…
View article: Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the main CD45+ cell populations identified in Supplementary Figure 5. Only genes with adjusted p-value < 0.01 and average log fold-change > 0.3 were included. gene, gene name; p_val, p-value calculated based on Wilcoxon te…
View article: Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Association between STK11 mutation and patient prognosis. In TCGA, STK11 mutations do not predict NSCLC OS.
View article: Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the monocyte-macrophage-DC subpopulations identified in Supplementary Figure 5H. Only genes with adjusted p-value < 0.01 and average log fold-change > 0.3 were included. gene, gene name; p_val, p-value calculated based on …
View article: Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 m…
View article: Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Time to 50% survival, in days, for mice engrafted with EMT6 tumors left untreated or treated with isotype control Ab or anti-PD-L1 plus anti-CTLA-4.
View article: Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
List of genes differentially expressed in STK11mut vs STK11wt tumors.
View article: Supplementary Table S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Clinical activity with durvalumab plus tremelimumab in patients from Study 006 with STK11mut and STK11wt tumors, characterized by tumor cell PD-L1 expression (high [{greater than or equal to}25%] or low [<25%]) and TMB (high [{greater than…
View article: Supplementary Figure S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Characterization of CT26 tumor cell lines with CRISPR-mediated STK11 loss. (A) Western blotting of STK11, phosphorylated AMPK (p-AMPK), total AMPK, and actin in lysates from wild-type CT26 cells (CT26 WT), STK11 CRISPR knock-out clones 26C…